論文業績

  1. Ogiso S, Okuno M, Shindoh J, Sakamoto Y, Mizuno T, Araki K, Goumard C, Nomi T, Ishii T, Uemoto S, Chun YS, Tzeng CD, Lee JE, Vauthey JN, Conrad C.
    Conceptual framework of middle hepatic vein anatomy as a roadmap for safe right hepatectomy.
    HPB (Oxford). 2019 Jan;21(1):43-50.
  2. Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Matsuyama Y, Unno M; Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP).
    Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
    Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194.
  3. Nakamura K, Sho M, Akahori T, Nagai M, Nishiwada S, Nakagawa K, Tanaka T, Kichikawa K, Tamamoto T, Hasegawa M, Mitoro A, Yoshiji H, Ikeda N.
    A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Cancer.
    World J Surg. 2019 Feb;43(2):642-648.
  4. 4. Nagai M, Sho M, Akahori T, Nishiwada S, Nakagawa K, Nakamura K, Tanaka T, Nishiofuku H, Kichikawa K, Ikeda N.
    Risk Factors for Late-Onset Gastrointestinal Hemorrhage After Pancreatoduodenectomy for Pancreatic Cancer.
    World J Surg. 2019 Feb;43(2):626-633.
  5. Motoi F, Murakami Y, Okada KI, Matsumoto I, Uemura K, Satoi S, Sho M, Honda G, Fukumoto T, Yanagimoto H, Kinoshita S, Kurata M, Aoki S, Mizuma M, Yamaue H, Unno M; Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS).
    Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.
    World J Surg. 2019 Feb;43(2):634-641.
  6. Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M, Tsuchida A, Unno M; Study Group of Preoperative therapy for Pancreatic cancer (PREP).
    A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
    J Gastroenterol. 2019 Feb;54(2):194-203.
  7. Nishiguchi Y, Fujiwara-Tani R, Sasaki T, Luo Y, Ohmori H, Kishi S, Mori S, Goto K, Yasui W, Sho M, Kuniyasu H.
    Targeting claudin-4 enhances CDDP-chemosensitivity in gastric cancer.
    Oncotarget. 2019 Mar 15;10(22):2189-2202.
  8. Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, Honda G, Uemura K, Okada KI, Matsumoto I, Nagai M, Yanagimoto H, Kurata M, Fukumoto T, Mizuma M, Yamaue H, Unno M; Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS).
    Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    BMC Cancer. 2019 Mar 21;19(1):252.
  9. Tsujimoto A, Ueda T, Kuge H, Inoue T, Obara S, Nakamoto T, Sasaki Y, Nakamura Y, Koyama F, Sho M.
    Long-term survival after adrenal metastasectomy from colorectal cancer: a report of two cases.
    Surg Case Rep. 2019 Apr 15;5(1):61.
  10. Wakatsuki K, Matsumoto S, Migita K, Kunishige T, Nakade H, Miyao S, Sho M.
    Prognostic value of the fibrinogen-to-platelet ratio as an inflammatory and coagulative index in patients with gastric cancer.
    Surg Today. 2019 Apr;49(4):334-342.
  11. Matsumoto S, Wakatsuki K, Migita K, Nakade H, Kunishige T, Miyao S, Sho M.
    Anastomotic leakage following retrosternal pull-up.
    Langenbecks Arch Surg. 2019 May;404(3):335-341.
  12. Nagakawa Y, Sahara Y, Hosokawa Y, Murakami Y, Yamaue H, Satoi S, Unno M, Isaji S, Endo I, Sho M, Fujii T, Takishita C, Hijikata Y, Suzuki S, Kawachi S, Katsumata K, Ohta T, Nagakawa T, Tsuchida A.
    Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Ann Surg Oncol. 2019 Jun;26(6):1629-1636.
  13. Akahori T, Sho M, Yanagimoto H, Satoi S, Nagai M, Nishiwada S, Nakagawa K, Nakamura K, Yamamoto T, Hirooka S, Yamaki S, Ikeda N.
    Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
    Oncologist. 2019 Jun;24(6):749-e224.
  14. Shioyama E, Mitoro A, Ogawa H, Kubo T, Ozutsumi T, Kitagawa K, Yoshikawa M, Ueda S, Akahori T, Marugami NA, Hatakeyama K, Yamao J, Sho M, Ohbayashi C, Yoshiji H.
    A pancreatic mucinous cystic neoplasm undergoing intriguing morphological changes over time and associated with recurrent pancreatitis: A case report.
    Medicine (Baltimore). 2019 Jul;98(28):e16435.
  15. Nakagawa K, Sho M, Akahori T, Nagai M, Nakamura K, Takagi T, Tanaka T, Nishiofuku H, Ohbayashi C, Kichikawa K, Ikeda N.
    Significance of the inflammation-based prognostic score in recurrent pancreatic cancer.
    Pancreatology. 2019 Jul;19(5):722-728.
  16. Shibuya K, Jang JY, Satoi S, Sho M, Yamada S, Kawai M, Kim H, Kim SC, Heo JS, Yoon YS, Park JS, Hwang HK, Yoshioka I, Shimokawa T, Yamaue H, Fujii T.
    The efficacy of polyglycolic acid felt reinforcement in preventing postoperative pancreatic fistula after pancreaticojejunostomy in patients with main pancreatic duct less than 3 mm in diameter and soft pancreas undergoing pancreatoduodenectomy (PLANET-PJ trial): study protocol for a multicentre randomized phase III trial in Japan and Korea.
    Trials. 2019 Aug 9;20(1):490.
  17. Tanaka T, Sato T, Nishiofuku H, Masada T, Tatsumoto S, Marugami N, Otsuji T, Kanno M, Koyama F, Sho M, Kichikawa K.
    Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
    BMC Cancer. 2019 Aug 1;19(1):758.
  18. Migita K, Matsumoto S, Wakatsuki K, Kunishige T, Nakade H, Miyao S, Sho M.
    Postoperative Serum C-Reactive Protein Level Predicts Long-term Outcomes in Stage I Gastric Cancer.
    J Surg Res. 2019 Oct;242:323-331.
  19. Sasaki T, Fujiwara-Tani R, Kishi S, Mori S, Luo Y, Ohmori H, Kawahara I, Goto K, Nishiguchi Y, Mori T, Sho M, Kondo M, Kuniyasu H.
    Targeting claudin-4 enhances chemosensitivity of pancreatic ductal carcinomas.
    Cancer Med. 2019 Nov;8(15):6700-6708.
  20. Yoshikawa T, Nomi T, Sakai K, Hayakawa M, Hokuto D, Matsuo Y, Sho M, Matsumoto M.
    Ischaemia-reperfusion injury with Pringle's maneuver induces unusually large von Willebrand factor multimers after hepatectomy.
    Thromb Res. 2019 Nov;183:20-27.
  21. Sasaki Y, Hokuto D, Inoue T, Nomi T, Yoshikawa T, Matsuo Y, Koyama F, Sho M.
    Significance of Herpesvirus Entry Mediator Expression in Human Colorectal Liver Metastasis.
    Ann Surg Oncol. 2019 Nov;26(12):3982-3989.
  22. ishiguchi Y, Oue N, Fujiwara-Tani R, Sasaki T, Ohmori H, Kishi S, Mori S, Mori T, Ikeda N, Matsumoto S, Wakatsuki K, Luo Y, Yasui W, Sho M, Kuniyasu H.
    Role of Metastasis-Related Genes in Cisplatin Chemoresistance in Gastric Cancer.
    Int J Mol Sci. 2019 Dec 30;21(1):254.
  23. Kamitani N, Migita K, Matsumoto S, Wakatsuki K, Kunishige T, Nakade H, Miyao S, Sho M.
    Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
    Surg Today. 2019 Dec;49(12):1022-1028.